Invention Grant
![Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents](/docs/US/2011-05-24/US07947676B2/abs.jpg.600x600.jpg)
- Patent Title: Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
- Patent Title (中): 吡唑并[3,4-d]嘧啶化合物作为抗肿瘤剂
-
Application No.: US11792921Application Date: 2005-12-12
-
Publication No.: US07947676B2Publication Date: 2011-05-24
- Inventor: Bernard Christophe Barlaam , Richard Ducray , Jason Grant Kettle
- Applicant: Bernard Christophe Barlaam , Richard Ducray , Jason Grant Kettle
- Applicant Address: SE Sodertalje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Sodertalje
- Agency: Morgan Lewis & Bockius LLP
- Priority: EP04292982 20041214; EP05291158 20050530
- International Application: PCT/GB2005/004770 WO 20051212
- International Announcement: WO2006/064196 WO 20060622
- Main IPC: C07D267/10
- IPC: C07D267/10 ; C07D413/14 ; C07D487/04 ; A61K31/519 ; A61K31/497 ; A61K31/5355 ; A61K31/553 ; A61P35/04
![Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents](/abs-image/US/2011/05/24/US07947676B2/abs.jpg.150x150.jpg)
Abstract:
The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
Public/Granted literature
- US20080108613A1 Pyrazolopyrimidine Compounds as Antitumor Agents Public/Granted day:2008-05-08
Information query
